Business Context and Reporting Period
Company: AgEagle Aerial Systems Inc. (UAVS)
Filing Type: Form 8-K (Current Report)
Date of Report: November 15, 2023
Principal Executive Offices: Wichita, Kansas
This filing reports the entry into material definitive agreements and the sale of equity securities on November 15, 2023, involving a proposed private placement of Series F Preferred Stock, associated warrants, and Common Stock.
Key Financial Metrics and Transactions
The filing details specific capital raising activities rather than periodic financial performance metrics (revenue, profit, cash flow). Key transaction values include:
- Series F Preferred Stock Sale: Investors purchased 1,850 shares of Series F Preferred Stock for an aggregate purchase price of $1,850,000.
- Common Stock Sale: The Company sold 1,500,000 shares of Common Stock to three accredited investors at $0.10 per share for an aggregate purchase price of $150,000.
- Warrant Issuance:
- Investor Warrants: Warrants to purchase up to 14,835,605 shares of Common Stock at an exercise price of $0.1247 per share (3-year term).
- Placement Agent Warrants: Dawson James Securities, Inc. received warrants to purchase 1,483,560 shares of Common Stock (10% of total warrants sold) with a 5-year term and no anti-dilution protection.
- Conversion Terms: The Series F Preferred Stock is convertible into 14,835,605 shares of Common Stock at a conversion price of $0.1247 per share.
Note: The filing text does not provide clear values for revenue, profit, cash flow, margins, total debt, or liquidity positions.
Material Changes and Agreements
The Company executed three primary agreements on November 15, 2023:
- Engagement Agreement: Appointed Dawson James Securities, Inc. as the sole placement agent on a reasonable best efforts basis for the Offering.
- Assignment, Waiver and Amendment Agreement:
- Assigned rights to purchase up to $1,850,000 of Series F Preferred Stock from an existing institutional investor to new assignees.
- Extended the deadline for the investor to exercise the "Additional Investment Right" from August 3, 2024, to February 3, 2025.
- Granted a one-time waiver of the $2,000,000 minimum subscription requirement to allow the exercise of the assigned rights.
- Securities Purchase Agreement: Sold Common Stock pursuant to an effective Form S-3 Registration Statement (No. 333-252801).
Outlook, Risks, and Unusual Items
Management Commentary and Outlook: The filing indicates active capital raising efforts to secure funding through a mix of preferred stock, common stock, and warrants. The extension of the investment right deadline suggests ongoing negotiations or flexibility in capital deployment.
Risks and Contingencies:
- Dilution: The issuance of 14,835,605 conversion shares and 14,835,605 warrant shares (plus 1,483,560 placement agent warrants) represents significant potential dilution to existing common shareholders.
- Regulatory Compliance: The November Additional Warrants and Placement Agent Warrants are being sold in reliance on exemptions from registration under Section 4(a)(2) of the Securities Act and Rule 506.
- Future Filings: A prospectus supplement for the Common Stock sale is expected to be filed with the SEC on or before November 17, 2023.
Investor Verification Checklist
- Verify the final closing date and receipt of funds for the $1,850,000 Preferred Stock and $150,000 Common Stock transactions.
- Review the full text of the Engagement Agreement (Exhibit 10.1) for specific compensation terms beyond the 10% warrant fee.
- Confirm the exact number of shares outstanding post-transaction to assess the dilution impact of the 14.8M+ conversion and warrant shares.
- Monitor the filing of the prospectus supplement for the Common Stock sale by November 17, 2023.
- Check subsequent filings for any further exercises of the "Additional Investment Right" up to the new February 3, 2025 deadline.